Literature DB >> 3300543

Activity of phenothiazines against medically important yeasts.

Y Eilam, I Polacheck, G Ben-Gigi, D Chernichovsky.   

Abstract

Two phenothiazine compounds, trifluoperazine and chlorpromazine, inhibited growth in vitro of the five most common pathogenic yeasts, with MICs ranging from 10 to 40 micrograms/ml. Daily intraperitoneal injections of trifluoperazine (4 to 7 mg/kg of body weight) increased the survival of mice experimentally infected with Candida albicans or Cryptococcus neoformans. The potential use of these drugs against fungal meningitis is discussed.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3300543      PMCID： PMC174848          DOI： 10.1128/AAC.31.5.834

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

Review 1.  Infections in cancer patients.

Authors:  G P Bodey
Journal:  Cancer Treat Rev       Date:  1975-06       Impact factor: 12.111

2.  Activity of compound G2 isolated from alfalfa roots against medically important yeasts.

Authors:  I Polacheck; U Zehavi; M Naim; M Levy; R Evron
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

3.  Medical mycology in crisis.

Authors:  W E Bullock; G S Deepe
Journal:  J Lab Clin Med       Date:  1983-11

4.  Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States.

Authors:  R L Stiller; J E Bennett; H J Scholer; M Wall; A Polak; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

5.  The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapy-induced emesis.

Authors:  G Wampler
Journal:  Drugs       Date:  1983-02       Impact factor: 9.546

6.  Aspergillosis and other systemic mycoses. The growing problem.

Authors:  D W Fraser; J I Ward; L Ajello; B D Plikaytis
Journal:  JAMA       Date:  1979-10-12       Impact factor: 56.272

Review 7.  Antifungal agents used in systemic mycoses. Activity and therapeutic use.

Authors:  J R Graybill; P C Craven
Journal:  Drugs       Date:  1983-01       Impact factor: 9.546

8.  Active extrusion of potassium in the yeast Saccharomyces cerevisiae induced by low concentrations of trifluoperazine.

Authors:  Y Eilam; H Lavi; N Grossowicz
Journal:  J Gen Microbiol       Date:  1985-10

9.  Effects of phenothiazines on inhibition of plasma membrane ATPase and hyperpolarization of cell membranes in the yeast Saccharomyces cerevisiae.

Authors:  Y Eilam
Journal:  Biochim Biophys Acta       Date:  1984-02-15

10.  Membrane effects of phenothiazines in yeasts. I. Stimulation of calcium and potassium fluxes.

Authors:  Y Eilam
Journal:  Biochim Biophys Acta       Date:  1983-09-07
  10 in total
  15 in total

Review 1.  Pathogenic roles for fungal melanins.

Authors:  E S Jacobson
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 2.  Antifungal activity of nonantifungal drugs.

Authors:  J Afeltra; P E Verweij
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-06-26       Impact factor: 3.267

3.  In vitro evaluation of the effectiveness of the macrolide rokitamycin and chlorpromazine against Acanthamoeba castellanii.

Authors:  A Mattana; G Biancu; L Alberti; A Accardo; G Delogu; P L Fiori; P Cappuccinelli
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

4.  Thioridazine inhibits gene expression control of the cell wall signaling pathway (CWI) in the human pathogenic fungus Paracoccidioides brasiliensis.

Authors:  Daniela Leite Jabes; Ana Claudia de Freitas Oliveira; Valquíria Campos Alencar; Fabiano Bezerra Menegidio; Débora Liliane Souza Reno; Daiene Souza Santos; David Aciole Barbosa; Renata Ozelami Vilas Boas; Rodrigo Luiz de Oliveira Rodrigues Cunha; Tiago Rodrigues; Regina Costa de Oliveira; Luiz R Nunes
Journal:  Mol Genet Genomics       Date:  2016-03-08       Impact factor: 3.291

5.  A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis.

Authors:  Arielle Butts; Louis DiDone; Kristy Koselny; Bonnie K Baxter; Yeissa Chabrier-Rosello; Melanie Wellington; Damian J Krysan
Journal:  Eukaryot Cell       Date:  2012-12-14

6.  Susceptibility of melanized and nonmelanized Cryptococcus neoformans to the melanin-binding compounds trifluoperazine and chloroquine.

Authors:  Y Wang; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 7.  Cryptococcal therapies and drug targets: the old, the new and the promising.

Authors:  Carolina Coelho; Arturo Casadevall
Journal:  Cell Microbiol       Date:  2016-04-08       Impact factor: 3.715

8.  Use of DBA/2N mice in models of systemic candidiasis and pulmonary and systemic aspergillosis.

Authors:  R F Hector; E Yee; M S Collins
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

9.  cAMP regulates vegetative growth and cell cycle in Candida albicans.

Authors:  Ajay Singh; Sadhna Sharma; Gopal K Khuller
Journal:  Mol Cell Biochem       Date:  2007-06-08       Impact factor: 3.396

10.  In vitro synergistic effects of chlorpromazine and sertraline in combination with amphotericin B against Cryptococcus neoformans var. grubii.

Authors:  Luana Rossato; Érico S Loreto; Régis A Zanette; Francieli Chassot; Janio M Santurio; Sydney H Alves
Journal:  Folia Microbiol (Praha)       Date:  2016-02-04       Impact factor: 2.099
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.